Trastuzumab resistance was reported in patients with breast cancers that were PTEN-negative in immunohistochemistry (30), however, a systematic delineation of the presence of PTEN in different cellular compartments in breast cancer lesions is highly warranted, particularly in the light of recent studies implying that drug resistance can be generated through tumor stroma (31–34). This evidence concerns the gene PTEN and neoplasm.